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S_ury 1The aims of the trial were to estabish the response rate and determine the toxxity ofcombination
chemotherapy with ifospamide, vincristine and spatin (HOP regimn) in advanced metastatic seminoma
and to study the role of post-chemotherapy consdation treatment Patients with bulky metasatic non-s-
fetoprotein-producing seminos were eligible for this phase II study [serum human chorionic gonado-
tropin<20OUI1' (<40ng1-')] if they pested with abdomial masses > 10cm or had extra-gonadal
seminoma or had relapsed after previous radiotherapy. The HOP regimen consisted of four 3-weekly cycles of
the following drug combination ifosphamide (days 1-5, 1 2mgm2 day-'), vincristin (day 1, 2mg) and
cisplatin (days 1-5, 20mgm-2 day-'). Residual masses persisting 6 months after chemotherapy could be
considered for consolidation surgery or radiotherapy. Maximal response to the HOP chemotherapy (evaluated
at any time) was based on the WHO criteria. The median observation time was 2.5 years (range 1.8-5.5
years). Thirtee institutions treated 42 eigible patints within the study (testcular cancer stage>IID, 25;
extragonadal, 5; relapse after previous radiotherapy, 12). Two patients were not evaluable for response owing
to premature treatment discontinuation. Maximal response was as follows: complete n (CR), 26
(65%); partial remission (PR) 11 (28%); no change (NC), 2 (5%); p ve disse (PD), 1 (3%). Four
patients have died, three from their maElgnancy (two vithout preous irradation and one with prior
radiotherapy). The fourth patient died of treatment-related toxicity. The 3 year survival for all 42 eligible
patients was 90%. Dose reducion and treatment postponement were neceary in 25 and 14 patients
respectively. Ten patients experenced granuloytic fever. Previously irradiated patients tolerated chemotherapy
as well as non-irradiated patients. Im tely after HOP chemotherapy a mass perssted in 16 of 17 patients
with retoperitoneal masses of ) 100 mm at presentation. Thre of these residual lesions were resected within
the following 6 months showing complete necrosis. Four lesions dissolved spontaneously during the first year
of follow-up. Nine lesions persisted for > 1 year (one after consolidation radiotherapy) without leading to
relapse. Four of seven patients with miastinal lesions achived CR and three a PR after HOP chemotherapy.
The HOP chemotherapy mgimen is highly effective in patiets with advanced metastatic sin or those
elapsing after previous radiotherapy, but is assocated with a high risk of toxiity, i particular myelotoxxity.
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About 20% of patients with seminoma present with bulky
metastatic disease at the time ofdiagnosis (stage>I UC, Royal
Marsden Classification System, Peciham et al., 1979). While
most patients with low-volume disease (stage HA/B) can be
cured by extemal beam radiotherapy (Thomas, 1991), cis-
platin (DDP)-based chemotherapy is fiequently used in the
more advanced cases (stage>,HC) (Wettlaufer, 1984; Fried-
man et al., 1985; Pizzocaro et al., 1986; Fossa et al., 1987;
Loehrer et al., 1987; Wilkinson et al., 1988; Horwich et al.,
1992; Clemm et al., 1989; Schmoll et al., 1993; Mencel et al.,
1994). Up to 1987 most institutions used the same or a
similar combination of cytostatics in patients with non-
seminoma. During the 1980s oncologists lared to treat
patients with non-seminomatous testicular cancer according
to prognostic groups, mainly determined by the tumour
burden (MRC, 1985; Stoter et al., 1987; Bosl et al., 1988;
Einhorn et al., 1989). For seminoma patients no such prog-
nostic grouping existed in 1987. However, many cliniians
considered patients with stage>IEID as a 'high-risk' group
(HID = retroperitoneal tumours> 10cm in diameter). Patients
with extragonadal seminoma, who often present with very
bulky tumours, may also arbitrarily be categorised as high-
risk cases. Patients relapsing after previous radiotherapy or
non-cisplatin-containing chemotherapy have also been con-
sided as a 'high-risk' group by several investigators (Fossa
et al., 1987; Loehrer et al., 1987).
Most authors (Wettlaufer, 1984; Friedman et al., 1985;
Pizzocaro et al., 1986; FossA et al., 1987; Loehrer et al., 1987;
Wilkinson et al., 1988) have used three- or even four-drug
combination chemotherapy in patients with metastatic
seminoma. Vimblastn, cyclophosphamide, adriamycin, bleo-
mycin and/or vincristine have most often been selected. The
combination of cisplatin and etoposide today may be con-
sidered to be the standard treatment (Motzer, 1993). Based
on experience from patients with non-seminomatous germ
cel cancer, bleomycin has been most often appLied as the
drug of choice. However, bleomycin is associated with the
risk of hmg compiations in these often elderly patients with
an age-related reduction in kidney function. Another active
drug in the treatment of testicular cancer is ifosphamide
(IFM). As alkylating agents were used with some sucess in
the treatment of advanced seminoma before the introduction
of cisplatin (MacKenzie, 1966), [FM may be of particular
interest in treatment of this malignancy. For patients who
have received previous radiotherapy, myelosuppressive
chemotherapy can present particular problems. Vincrisine is
only partly myelosuppressive and has been used in drug
combinaons designed for seminoma patients (Wettlaufer,
1984).
In an attempt to improve the cure rate of 'high-risk'
patients, with metastatic seminoma as defined above, the
EORTC Genito-Urinary Group in 1987 designed a multi-
centre phase H study in patients with high-risk metastatic
seminoma. The present report presents the results of this
trial, which had three principal objectives:
1. To determine the response rate, time to progression and
overall survival in high-risk patients with metastatic
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seminoma treated with HOP combination chemotherapy
[H = Holoxan (Astra), 0 = Oncovin (Lilly) P = DDP].
2. To determine the toxicity of such treatment.
3. To evaluate the role of post-chemotherapy consolidation
treatment.
Patients and methods
Eligibility criteria
Patients with histologically verified pure testicular or extra-
gonadal seminoma without elevated a-fetoprotein (AFP)
values were included in this study. All known human
chorionic gonadotrophin (HCG) levels had to be <200 U l 1
(<40 ng ml-'). Untreated patients should have presented
with stage IID, III or IV disease (Peckham et al., 1979). All
patients relapsing after previous radiotherapy were eligible
for this protocol.
Before inclusion into the trial all patients had to undergo
physical examination with particular reference to palpable
lymph nodes, hepatomegaly and palpable abdominal masses.
Computerised tomography (CT) of the chest and abdomen
was performed in each patient together with determination of
serum HCG and AFP, haemoglobin, white blood count
(WBC), platelet counts, serum creatinine, serum electrolytes
and liver function tests. Eligible patients had to have a
creatinine clearance of at least 40 ml min-'. The size of the
indicator lesion was defined as the product of its largest
diameter and its perpendicular diameter, measured by clinical
examination or on a transverse CT section.
Treatment
According to the protocol each patient was to receive four
cycles of combination chemotherapy with IFM, vincristine
and DDP (HOP) given at 3 week intervals (Table I).
Four weeks after the last chemotherapy cycle the patients
were restaged by CT and other appropriate methods (for
example by bone scan in case of initial skeletal metastases).
In the case of complete response (see below) no further
treatment was given. In the case of residual tumour masses a
fine-needle aspiration biopsy was to be performed dunrng
week 13, if possible. If no malignant residual tumour cells
were found, the patient was to be observed at 6 week inter-
vals for the first 6 months without any consolidation treat-
ment as long as serial CT scans showed continuous shrinkage
of the residual post-chemotherapy masses. If the residual
mass stopped shrinking within 6 months of chemotherapy or
if there was a remaining mass 6 months after discontinuation
of chemotherapy, post-chemotherapy resection of the masses
was considered. No further treatment was given to patients
without vital malignant tumour cells in the operation speci-
men, whereas further chemotherapy or radiotherapy (at the
clinician's discretion) was to be given to patients in whom the
histological sections or fine-needle aspirates revealed residual
malignant tumour. If surgery was judged to be impossible in
an individual patient (mediastinal mass, poor general condi-
tion and/or old age), radiotherapy to the tumour-bearing
area was recommended.
Evaluation ofresponse
Response evaluation was to be done in all eligible patients
regardless of the number of chemotherapy cycles which were
given ('intention to treat'). Measurement of the indicator
Table I HOP combination chemotherapy (apphed four times every 3
weeks)
Day I Day 2 Day 3 Day 4 Day 5
IFMa 1200mgm- X X X X X
Vincristine 2 mg X
DDP 20mgm- X X X X X
aCombined with Mesna 1200 mgm-2.
lesion(s) was routinely performed 4 weeks after the start of
the last chemotherapy cycle (week 13). In patients who at
that time had residual masses new measurements were to be
taken at 3 month intervals. The original definition of PR and
NC required the presence of histologically or cytologically
verified residual malignancy. Post-chemotherapy histology
was, however, obtained in only four patients. The final
evaluation of response to HOP chemotherapy of non-resected
masses was therefore based on measurements of the lesion(s)
alone. The maximal response ever obtained by the HOP
regimen was defined as follows:
Complete response. No detectable tumour at clinical or
radiological examination. Normal serum HCG levels
or
Patients with subsequent surgery revealing no vital malignant
tumour in the operation specimen (four cases).
Partial response (PR). Tumour shrinkage by > 50% fol-
lowing chemotherapy.
No change (NC). <50% reduction or <25% increase of
an indicator lesion.
Progression (PD). Increase of initial tumour size by more
than 25% or appearance of new tumour lesions or increase
of serum HCG by at least 25% of the initial value.
Cytological or histological proof of malignant growth was
recommended but not mandatory.
Drug toxicity
Before each chemotherapy cycle physical examination was
performed along with haemoglobin, WBC, platelets, serum
creatinine, serum electrolytes and liver function tests. On day
15 of each cycle haemoglobin, WBC, platelets and serum
creatinine were determined. The urine sediment was checked
daily during ifosphamide treatment.
If WBC fell below 1.5 x 1091' or the platelet count below
50 x 109 1-l at the scheduled start of a chemotherapy cycle,
the treatment was delayed for 1 week. If after 1 week the
counts had not improved, the patient went off study. Appro-
priate dose modifications were made for ifosphamide and
cisplatin in case of WBC between 1.5 and 3.0x 1091-' or
platelets 15-I00 x 1091-' on day 21 of a cycle. The DDP
dose was not reduced in case of renal function impairment
unless the creatinine clearance was below 40 ml min-'. In this
case, DDP was temporarily reduced but subsequently
resumed at a dose of 75% of the prior dose. Ifosphamide was
permanently discontinued if the creatinine clearance fell
below 40 ml min-'. Non-haematological toxicity (allergic
reaction, peripheral neuropathy, urotoxicity, cerebral toxicity,
urothelial toxicity) was regularly monitored.
Statistics
According to clinical judgement, the lowest CR rate of prac-
tical importance was 90%. Assuming that there was a 50%
chance that the HOP combination chemotherapy would have
a CR rate of approximately 80% and a 50% chance that it
had a CR rate of 95%, the optimal restricted Bayes sampling
plan was to enter 40 patients and reject the combination if 35
or fewer responses were observed. This plan would yield a
type I error of 0.075 and a type II error of 0.05. Survival was
calculated according to the Kaplan-Meier method.
Results
From March 1988 to January 1992 13 institutions entered 51
patients with histologically proven seminoma into the study
(Table II). Nine patients were finally deemed to be ineligible.
For one of the 51 patients, no case record forms were
received at the data centre after registration. In three patients
revision of the pathological sections revealed histology
incompatible with seminoma. Two other patients presenting
with small multiple lung densities were initially categorised as
having stage IV disease. It subsequently became obvious that
the pulmonary nodules were sequelae of virus-induced pneu-monia and tuberculosis. One patient had serum AFP eleva-
tion above the institution's reference range, and in the two
remaining patients the tumour stage was <IID. Among the
remaining 42 patients, 25 had newly diagnosed stage IID,
stage III or stage IV testicular cancer, five patients presented
with an extragonadal germ cell tumour and 12 patients pres-
ented with relapse after previous infradiaphragmatic
radiotherapy (26-40 Gy).
Response rate
In two of the 42 patients relevant measurements for response
evaluation were not performed: one went off study after the
first cycle because of a rapid decrease in his performance
status. He received three additional cycles with carboplatin
monotherapy and became tumour free. The other patient
died of a brain abscess after three cycles and before any
measurement of his mediastinal tumour could be made.
Twenty-six of the remaining 42 eligible patients achieved a
CR [62%, 95% confidence interval (95% CI) 46-76%] and
11 patients a PR (26%, 95% CI 14-42%), two patients (5%)
were registered as NC, and one patient progressed. He had
received HOP chemotherapy for an in-field recurrence after
infradiaphragmatic radiotherapy. The total response rate was
thus 37 of 42 patients (88%, 95% CI 74-%%). Maximal
responses were observed after a median time of 104 days
(range 91-707 days). In none of the patients with PR or NC
was a fine-needle biopsy performed.
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unchanged during the observation period. None of these ten
patients with residual retroperitoneal lesions of >30 mm size
relapsed.
Four of seven non-irradiated supradiaphragmatic lesions
responded completely to HOP chemotherapy as evaluated
clinically and radiologically immediately after chemotherapy
(Figure lc). The three other masses displayed a PR. One of
these three partially responding patients relapsed 6 months
after HOP chemotherapy in spite of mediastinal consolida-
tion irradiation.
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Residual masses and consolidation treatment
Immediately after HOP chemotherapy the retroperitoneal
mass had completely disappeared in only 1 of 17 previously
non-irradiated patients in whom the initial retroperitoneal
lesion was .100 mm (Figure la and b). In six patients the
residual mass was <30 mm: three of these masses disap-
peared completely without further treatment during the first
year of follow-up. The other three lesions remained
unchanged. In ten patients a residual mass of >30 mm
persisted after four HOP cycles. In three of these ten patients
the lesion was resected within 6 months after chemotherapy.
Shrinkage by >50% of the immediate post-chemotherapy
size within the first year after chemotherapy was observed in
three of the remaining seven patients, in one of them leading
to CR. One of these 3 partially responding lesions was
irradiated 11 months after HOP therapy. In the last four
patients the retropenrtoneal mass persisted virtually
Table H Patient characteristics
Number of patients
Included
Ineligible
Not evaluable for response
Evaluable for treatment efficacy
(intention to treat)
Median age (years) (range)
Previous treatment
No
Radiotherapy
Stage
IID
III
IV
HCG (U 11')
Normal
Elevated
Median' (range)
Unknown
51
9
2
42
41 (35-66)
30
12
9a + 3b
12 + 2a
4d
IC
5c
6'
30
11
75 (13-193)
1
E
0
0
E
co
-n
J
0
-J
E
0
0
E
la
0
0
b
200
180
160
140
120
100
80
60
40
20
0
-20 -
110-
100-
90 -
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
0
in._
Post-treatment (months)
Time of evaluation
14 R
Pretreat- 0 3 6 9 12 >12 Pretreat- 0 3 6 9 12 >12
ment
Post-treatment (months)
,% Time of evaluation
Pretreat- 0
ment
3 6 9 12 >12
Post-treatment (months)
Time of evaluation
Figwe 1 Size changes in non-irradiated metastatic lymph nodes
in patients with advanced seminoma treated with combination
chemotherapy (ifosphamide, vincnstine, cisplatin). S, consolida-
tion surgery; R, consolidation radiotherapy; PD, progressive
disease. *Observation time (in months) without consolidation
treatment after the last measurement of residual masses. (a)
Infradiaphragmatic lesions 100- 119 mm before chemotherapy.
(b) Infradiaphragmatic lesions> 120 mm before chemotherapy. (c)
Mediastinal and supraclavicular lesions.
'Patients with no previous treatment and testicular cancer. bPatents
with no previous treatment and extragonadal tumours. CPafients with
previous treatment. 'Patients with no previous treatment. 'Only for
elevated serum levels.
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Only seven patients with residual lesions immediately after
chemotherapy underwent consolidation treatment. Three
patients underwent a complete resection of a retroperitoneal
or pelvic mass, and in a fourth patient a mediastinal mass of
20 mm diameter was removed 16 months after chemotherapy.
The histological examination showed complete necrosis in all
four patients. In three partially responding patients post-
chemotherapy radiotherapy was applied without a preceding
biopsy. No consolidation treatment was given to the remain-
ing patients with PR or NC.
Survival
All patients were observed until November 1993. After a
median follow-up time of 2.5 years (range 1.8-5.5 years)
four patients have died. A previously irradiated patient
(HCG increase, liver metastases) progressed immediately
after HOP chemotherapy and could not be salvaged. He died
10 months after trial entry. Two previously untreated
patients with initial stage III disease developed a CR or a PR
(residual mediastinal mass 30 mm), but relapsed 4 and 6
months, respectively, after treatment discontinuation and
subsequently died of their malignancy. A fourth patient died
from treatment-related toxicity (brain abscess after three
cycles).
The 3 year survival for all 42 patients was 90%. There are
too few events to make any meaningful comparison between
patients with or without prior radiotherapy or with or with-
out elevated pretreatment HCG levels.
Toxicity
Toxicity was evaluated in all 42 patients (Table III). A total
of 163 cycles (one cycle, one patient; three cycles, three
Table m Maximal toxicity in 42 patients
Grade
0 1 2 3 4 Unknown
Leucocytes 2a 4 18 17 1
Thrombocytes 13 11 3 7 6 2
No Yes
Granulocytopenic fever 32 10
Transiently reduced consciousness 37 5
Peripheral neuropathy 34 8
Treatment schedule modifications
Dose reduction 17 25
Delay of cycle 28 14
aNumber of patients.
patients; four cycles, 37 patients; five cycles, one patient) was
applied. Dose reductions were performed in 25 patients. Post-
ponement ofcycles was necessary in 14 patients. Ten patients
experienced granulocytopenic fever. No significant differences
in side-effects were observed between previously irradiated or
previously untreated patients.
Two patients developed a subsequent malignant tumour.
One patient with an extragonadal mediastinal seminoma but
no retroperitoneal mass developed non-seminomatous tes-
ticular cancer in his only testicle with histologically proven
carcinoma in situ before HOP chemotherapy. (His right tes-
ticle had been removed when he was 15 years old because of
maldescent). In the other patient a rectal carcinoma was
diagnosed 22 months after trial entry.
Dison
The optimal treatment of patients with highly advanced
seminoma (,>stage IID) or of those relapsing after radio-
therapy or of patients with extragonadal presentation is still
under discussion (Tables IV and V). Smalley et al. (1985)
recommend initial radiotherapy even in stage II patients with
retroperitoneal masses> O0cm. Several authors (Smalley et
al., 1985; Thomas, 1991) have shown that patients who have
a small-volume mediastinal or supraclavicular relapse after
radiotherapy for stage I seminoma can be cured by further
radiotherapy alone. Retrospectively one has to admit that
not all of our patients relapsing after radiotherapy repres-
ented 'high-risk' cases. The HOP regimen was probably over-
treatment in some of the previously irradiated patients with
limited supradiaphragmatic lymph node relapse. However,
Table IV Radiotherapy of previously untreated 'high-risk' patients
with advanced semninoma'
No. Survival
Reference patients Stage Relapse (%)
Ball et al. (1982) 14 IID NAb 78
Thomas et al. (1982) 12 IID 5 NAb
Schultz et al. (1984) 17 III + IV 5 66
Smalley et al. (1985) 12 IID NAb 100
Mason and Kearsley (1988) 12 IID 4 92
Smalley et al. (1990) 5 IIID 2 NAb
Dosmann and Zagars (1993) 13 IID 4 70
aOnly series for which the present high-riskcriteria were identifiable.
bNA, not available.
Table V Treatment of 'high-risk' patients with advanced seminoma, cisplatin-based chemotherapy
No. 'High-risk' Survivat
Referencea patients characteristic Chemotherapyb Failure (%j
Wettlaufer (1984) 12 III + IV Cy OP 1 94
Fnredman et al. (1985) 6 Previous treatment PVB 3 83
Pizzocaro et at. (1986) 12 IID PVB + A 75
3 III BEP-A (23)
6 IV PVB, BEP (2 3)
Loehrer et al. (1987) 33 Radiotherapy PVB, BEP 10 NA
FossA et al. (1987) 15 Radiotherapy PVB 6 50*
Wilkinson et al. (1988) 13 III BEP/Cy 69*
16 IV 33*
Clemm et al. (1989) 7 Radiotherapy VIP 2 (5 7)
Horwich et al. (1992) 22 Radiotherapy Carboplatin 95
Schmoll et al. (1993) 11 IID 2 NA
12 III Carboplatin 3 NA
3 IV 2 NA
Mencel et al. (1994) 33 Extragonadal Cisplatin- 100
18 Radiotherapy basedd 72
24 IV 79
aOnly thoseseries from the last 11 years for which the present'high-risk'categories were identifiable
are included. bCy, cyclophosphamide; 0, oncovin; P, platinum; V, vinblastine; B, bleomycin; E,
etoposide; A, adriamycin; Carbo, carboplatin. cCancer-specific survival, except * crude survival.
'Various combinations.chm w y
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when the present phase II study was initiated, no generally
accepted high-risk criteria for seminoma existed and the
eligibility criteria had to be arbitrarily defined with some
support from the literature (Fossa et al., 1987; Loehrer et al.,
1987). However, early reports on recurrent seminoma
patients probably inchlde previously irradiated patients with
more advanced relapses and thus a high risk of failure of
salvage treatment compared with those entered in the present
trial.
The optimal combination chemotherapy in high-risk
seminoma patients remains a matter of debate. Clinical
experience with bleomycin in elderly patients has taught that
this drug may be associated with a high-risk of pulmonary
complications, in particular if prior mediastinal irradiation
has been applied (Lehne and Lote, 1984). Wettlaufer (1984)
has designed a combination drug schedule in which
bleomycin is replaced by vincristine, a drug with minimal
bone marrow toxicity. The present HOP regimen represets a
modification of the Wettlaufer regimen, in which cyclophos-
phamide is replaced by ifosphamide, and which has shown
high activity in germ cell cancer. Compared with the relapse
and survival rates from Table IV and V, our 90% cancer-
specific survival rate demonstrates a high efficacy of the
chosen chemotherapy combination.
The study has, however, also indicated considerable tox-
icity of the HOP regimen: a 65-year-old man refused further
treatment after the first cycle because ofgeneral deterioration
(performance status WHO 4) and one patient died of tox-
icity. Grade 3 and 4 myelosuppresszon was observed at kast
once in 85% of the patients. The high incidence of severe
haematopoetic side-effects has to be balanced against the
Royal Marsden Hospital's (Horwich et al., 1992) and
Schmoll et al.'s (1993) experience with relatively non-toxic
carboplatin monotherapy. These investigators obtained excel-
lent final results with single-drug carboplatin chemotherapy
in patients with metastatic seminoma. On the other hand, a
30% relapse rate was demonstrated. Such a high recurrence
rate is felt unacceptable by many clinicians.
Several authors have expressed concern about chemo-
therapy tolerability after previous radiotherapy for seminoma
(Pizzocaro et al., 1986; Motzer et al., 1988). However,
according to Pizzocaro et al. (1986) and Fossa and Aamdal
(1992), patients who have received infradiaphragmatic
radiotherapy alone tolerate cisplatin-based chemotherapy as
well as previously untreated patients. This is also our
experience with the HOP chemotherapy. This observation is
important as it does not contradict the present recommenda-
tion of infradiaphragnatic radiotherapy as standard treat-
ment for seminoma stage I. Whether the combination of
moderate-dose infradiaphragmatic radiotherapy and subse-
quent salvage chemotherapy in relapsing patients leads to an
increased risk of long-term toxcity renains to be shown in
future studies.
The role of routine consolidation treatment after chemo-
therapy for advanced seminoma has been intensively dis-
cussed (Friedman et al., 1985; Fossa et al., 1987; Motzer et
al., 1987; Ellison et al., 1988; Wilkinson et al., 1988; Horwich
et al., 1992). Some authors have recommended the routine
removal of residual masses a few months after chemotherapy
(Motzert al., 1987). Others (Schultz et al., 1989; Horwich
et al., 1992) have advised observation or radiotherapy to
increase the chance of local control. In series which consider
post-chemotherapy surgery, 85-90% of the residual masses
contain fibrosis and necrosis. As post-chemotherapy surgery
in patients with advanced seminoma represents a surgical
procedure with a relatively high risk of per- and post-
operative complications, it does not seem justified to operate
immediately in all patients in whom masses persist after
chemotherapy. The present seres supports this recommenda-
tion. Patients with lesions persisting after chemotherapy can
as a rule be safely observed for up to 1 year, allowing fiuther
shrinkage of the mass. Though the present series comprises
only ten evaluable patients, this recommendation also refers
to residual tumours with a diameter .30 mm after HOP
chemotherapy. Lesions of this size have, in some authors'
experience, been proven particularly often to contain residual
malignancy (Motzer et al., 1987). In our experience three of
three resected residual retroperitoneal masses of that size and
one mediastinal esion contained complete necrosis. None of
the six patients with long-term prsisting retroperitoneal or
mediastinal tumours without consolidation treatment have
relapsed after a median observation time of 2.5 years.
Our results underline the difficulies in defining clinical
criteria of response to chemotherapy in patients with
advanced seminoma. Residual masses persist frequently and
are often unsuitable for surgery. Furthermore, a clinical PR
often represents a pathological CR. Our experience also
indicates that clinicians do not believe in the significnce of
fine-needle biopsies, which may miss tiny tumour foci in a
large fibrotic mass. If possible, a bidimensionally measurable
response should not be assessed before 6 months has elapsed,
allowing long-term post-chemotherapy shrinka. The effi-
cacy of chemotherapy in advanced seminoma should, how-
ever, preferably be evaluated by more meaningful biological
parameters: time to progression and cancer-related survival.
In conclusion, the HOP chemotherapy rgmen is highly
effective in patients with bulky metastabtc seminoma (stage
> IID, patients relapsing after radiotherapy, extragonadal
presentation), but represents a relatively toxic treatment. Less
toxic regimens are probably to be preferred in patients with
low-volume disease. Previous infradiaphragmatic moderate-
dose radiotherapy for seminoma does not imply a particular-
ly high nsk of complications. After HOP chemotherapy
routine post-chemotherapy consolidation treatment (surgery,
radiotherapy) seems unnecessary in the overwhelming
majority of the patients. According to our ongoing observa-
tions nkage of residual masses can be expected for at
least 1 year following chemotherapy.
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lands; PHM de Mukler, St Radboud Hospital, Nemegen, The
Netherlands F Keuppens, Academic Hospital, Free University,
Brussls, Belgium; S Rodenhuis, The Netherlands Cancer Institute,
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